Jean Jacques Bienaime - Apr 11, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Apr 11, 2024
Transactions value $
-$1,121,000
Form type
4
Date filed
4/15/2024, 04:21 PM
Previous filing
Mar 19, 2024
Next filing
May 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $1.26M +20K +4.21% $63.10 495K Apr 11, 2024 Direct F1
transaction BMRN Common Stock Sale -$1.82M -20K -4.04% $90.99 475K Apr 11, 2024 Direct F1
transaction BMRN Common Stock Options Exercise $1.26M +20K +4.21% $63.10 495K Apr 12, 2024 Direct F1
transaction BMRN Common Stock Sale -$1.83M -20K -4.04% $91.26 475K Apr 12, 2024 Direct F1
holding BMRN Common Stock 247K Apr 11, 2024 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 Apr 11, 2024 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 Apr 11, 2024 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -20K -15.27% $0.00 111K Apr 11, 2024 Common Stock 20K $63.10 Direct F2
transaction BMRN Stock Option (Right to Buy Common Stock) Options Exercise $0 -20K -18.02% $0.00 91K Apr 12, 2024 Common Stock 20K $63.10 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.